McKesson (MCK) is a 'Buy' with high-growth potential in healthcare services. Learn key risks and outlook for stock ...

McKesson (MCK) stock earns a BUY rating as it excels in tech-driven healthcare, specialty growth, and strong earnings ...

McKesson's fair value estimate has been raised from $793.21 to $829.57, driven by an improved outlook from analysts following ...

McKesson (MCK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

McKesson Corp on Tuesday said it and two other major U.S. drug distributors could be expected to pay up to $21 billion under a new proposal to resolve thousands of lawsuits alleging they helped fuel ...

McKesson (NYSE: MCK) has outperformed the market over the past 10 years by 2.25% on an annualized basis producing an average annual return of 14.73%. Currently, McKesson has a market capitalization of ...

McKesson MCK is making a strategic shift that will redefine its role in the healthcare ecosystem. Long known as one of the ...

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The U.S. Supreme Court on Monday sided with Black Lives Matter activist DeRay McKesson in his ongoing effort to avoid a lawsuit filed by a police officer injured during a 2016 protest in Louisiana ...

InspiroGene™ by McKesson today announced the publication of its second annual 2025 Cell and Gene Therapy Report: Advancing the Future of Medicine.

Oath Surgical is building the future of surgical care: surgeon-led, AI-powered, and value-based by design. The first vertically integrated system combining AI software and tech-first surgical centers, ...